早期周围型肺癌的支气管镜治疗:是否已准备好进入主流?
本文综述了早期周围型非小细胞肺癌(NSCLC)的支气管镜消融治疗现状。手术切除仍是首选,但许多患者因合并症或高龄无法手术,立体定向消融放疗(SABR)有效但部分患者禁忌,经皮消融并发症较多。多种支气管镜消融技术正在评估中,具有更优安全性及单次操作即可诊断分期的潜力,作者探讨其作用及建立常规应用的路径。
要点
- 手术切除仍是早期NSCLC首选,但合并症和高龄常限制手术。
- SABR有效但部分患者因既往放疗、合并症或肿瘤位置禁忌。
- 支气管镜消融技术安全性和诊断分期一体化潜力值得评估。
核心结论
- 支气管镜消融技术具有更优安全性和单次操作诊断分期的潜力,但尚需评估以确立常规应用。
研究设计与样本
- 综述文章,探讨支气管镜消融在周围型肺肿瘤治疗中的作用及建立常规应用的路径。
主要发现
- 手术切除是早期NSCLC首选,但合并症和高龄常限制手术。
- SABR是有效模式,但部分患者因既往放疗、合并症或中心位置肿瘤而禁忌。
- 经皮消融方法可用但常伴显著并发症。
- 多种支气管镜消融技术正在评估中,具有更优安全性和单次操作诊断分期的潜力。
临床怎么用
- 对于无法手术的早期周围型NSCLC患者,支气管镜消融可能成为SABR和经皮消融的替代选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lung cancer is the leading cause of cancer-related death worldwide and surgical lobectomy remains the preferred therapy for patients with early-stage NSCLC. Medical comorbidities and advanced age preclude resection in many patients and minimally invasive ablative therapies are needed for treatment. Stereotactic ablative radiation is established as an effective modality in this patient group, although may be contraindicated in some patients with prior radiation exposure, comorbidities or centrally positioned tumours. Percutaneous ablative methods are available, although are frequently associated with significant complications. Numerous endoscopic ablative techniques are under evaluation. With a more favourable safety profile and the ability to provide diagnosis and staging information potentially within a single procedure, there is a strong rationale for development of bronchoscopic ablative modalities. In the following article, the authors aim to explore the role bronchoscopic ablation may play in treatment of peripheral lung tumours, and to describe a pathway to establishing these modalities as part of routine care. The current status of several bronchoscopic ablative options is discussed in detail.
引用
- Steinfort DP, Herth FJF. Bronchoscopic treatments for early-stage peripheral lung cancer: Are we ready for prime time? Respirology. 2020. PMID: 32643221. doi:10.1111/resp.13903
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。